Home|Journals|Articles by Year|Audio Abstracts

Research Article

The Incidence of Adverse Effects of Monoclonal Antibodies in Breast and Gynec Cancer Patients



Objectives: This study focuses on the severity of the adverse effects induced by monoclonal antibodies in Indian population. This study is performed in a multispecialty hospital and adverse effects were monitored in the study population. Therefore, the main objective of the study was active surveillance of adverse effects induced by monoclonal antibodies.
Methodology: A cohort study was conducted in 120 patients with breast and gynaecological cancer for a period of 6 months in a multispecialty hospital.
Result: Among 120 patients Breast cancer was the most prevalent followed by cervical cancer. Adverse effects were seen in all age groups, most adverse effects were reported with Trastuzumab (37.50%) and Bevacizumab (26.78%). Monoclonal antibodies were well tolerated by the patients with minimum adverse effects which are manageable with supportive therapy, the most prevalent adverse effect was anaemia.
Conclusion: By assessing Adverse effects using Naranjo scale, most of them were found to be possible (32%) and probable (67%). In WHO scale, the most of the adverse effects were also follow under category of possible (38.14%) and probable (61.20%). Of all adverse effects no severe adverse effects were seen in the patients, i.e. monoclonal antibodies were well tolerated by the patients.

Key words: Naranjo Scale, WHO Scale, Monoclonal Antibodies, Breast cancer, Gynaecological cancers

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.